The Recall Desk

Hazard

Cross Contamination recalls

435 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
435
Critical
6
Severe
157
Most recent
2026-07-29

Of the 435 cross contamination recalls we have scored against our rubric, 6 (1%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 157 (36%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all cross contamination recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

351–375 of 435

  • SevereFDA (Drugs)·D-954-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vincristine Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vincristine Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Vincristine Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-556-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcitriol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling calcitriol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Calcitriol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-813-2015·2015-04-29

    Attix Pharmaceuticals Recalls Naproxen Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Naproxen Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Naproxen Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-890-2015·2015-04-29

    Attix Pharmaceuticals Recalls Seratonin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Seratonin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed nationwide to compounding pharmacies and research organizations.

    Product
    Seratonin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-627-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dexrazoxane Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Dexrazoxane active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dexrazoxane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-846-2015·2015-04-29

    Attix Pharmaceuticals Recalls Podophyllum Resin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Podophyllum Resin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Podophyllum Resin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-507-2015·2015-04-29

    Aldosterone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Aldosterone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Aldosterone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-741-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ketoconazole API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Ketoconazole active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Ketoconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-784-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methocarbamol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling methocarbamol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methocarbamol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-616-2015·2015-04-29

    Attix Pharmaceuticals Recalls Darunavir API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Darunavir active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Darunavir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-615-2015·2015-04-29

    Attix Pharmaceuticals Recalls Daptomycin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Daptomycin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Daptomycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-608-2015·2015-04-29

    D-Cycloserine API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling D-Cycloserine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    D-Cycloserine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-492-2015·2015-04-29

    Attix Pharmaceuticals Recalls 4-Aminopyridine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 4-Aminopyridine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    4-Aminopyridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-935-2015·2015-04-29

    Tolvaptan API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Tolvaptan active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tolvaptan active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-852-2015·2015-04-29

    Attix Pharmaceuticals Recalls Povidone K-30 Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Povidone K-30 pharmaceutical ingredient lots distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Povidone K-30 pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-881-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ritonavir API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ritonavir active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ritonavir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-579-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chloroquine Phosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chloroquine Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chloroquine Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-551-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupivacaine Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupivacaine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed nationwide to compounding pharmacies and research organizations.

    Product
    Bupivacaine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-940-2015·2015-04-29

    Trazodone HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Trazodone HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Trazodone HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-703-2015·2015-04-29

    Attix Pharmaceuticals Recalls Heparin Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Heparin Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Heparin Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-609-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dacarbazine Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Dacarbazine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dacarbazine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-884-2015·2015-04-29

    Attix Pharmaceuticals Recalls Roflumilast API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Roflumilast active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Roflumilast active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-778-2015·2015-04-29

    Attix Pharmaceuticals Recalls Memantine HCl Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Memantine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Memantine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-561-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carbimazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carbimazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Carbimazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-848-2015·2015-04-29

    Attix Pharmaceuticals Recalls Polidocanol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Polidocanol (Industrial Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Polidocanol (Industrial Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide